Siemens Healthineers plans two-step 7.5 bln euro capital hike for Varian acquisition -sources
* First stage of cap hike expected later this year -sources
* Varian shares spike, while Healthineers shares plunge
* (Adds details about structure of capital increase from sources, share price)
MUNICH, Aug 3 (Reuters) - Siemens Healthineers
The German health group said on Sunday it was buying U.S. peer Varian in a $16.4 billion deal that seeks to create the global leader in cancer care solutions.
Varian shares rose 22% in early trading on Monday, while Healthineers' shares were down 6.7% at 41.00 euros each on concerns that Healthineers was paying a steep price.
Healthineers said on Sunday that it would pay $177.50 each for Varian shares, a 24% premium to the shares' closing price on Friday.
Shares in parent company Siemens, however, rose 3.7% on Monday to 112.28 euros.
Healthineers said it plans to raise roughly 7.5 billion euros in equity to finance the deal, with the remainder coming from debt that parent Siemens will provide.
To avoid raising the money through a rights issue, Healthineers plans to place up to 10% of shares on the market using its authorised capital later this year. The company will seek shareholder approval for a similar transaction next year, the sources said.
Siemens' stake in Healthineers will be diluted to about 72% from 85% following the share sale.
The debt part of the transaction will be provided by parent
By buying Varian, Healthineers is acquiring the leader in radiation therapy with a market share of over 50%. In case the deal falls through, Siemens will have to pay a $450 million break fee. ($1 = 0.8522 euros) (Reporting by Joern Poltz and Arno Schuetze Editing by Sabine Wollrab, Thomas Seythal and Susan Fenton) ((MichelleHannah.Martin@thomsonreuters.com; +49 30 2888 5223; Reuters Messaging: MichelleHannah.Martin.email@example.com)) Keywords: VARIAN MED SYST M&A/SIEMENS HEALTH FINANCING (UPDATE 1, PIX)
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.